JangoPet Biologics
Age-related decline in companion animals (dogs)
Veterinary Clinical StudyActive
Key Facts
Indication
Age-related decline in companion animals (dogs)
Phase
Veterinary Clinical Study
Status
Active
Company
About JangoBio
JangoBio is a private, pre-clinical biotech advancing a novel approach to treating age-related decline by addressing hypogonadism—the loss of sex hormone-producing cells. The company is developing hormone-producing organoids derived from stem cells to rebalance the reproductive axis, with initial applications in companion animals (JangoPet) to generate data and revenue for future human trials. Its business model combines early revenue from service-based subsidiaries (JangoCell, JangoDx) with a long-term focus on developing allogeneic cell therapies for human age-related diseases.
View full company profile